TY  - CHAP
M1  - Book, Section
TI  - Depigmenting Agents
A1  - Baumann, Leslie
A1  - Allemann, Inja Bogdan
A2  - Baumann, Leslie
A2  - Saghari, Sogol
A2  - Weisberg, Edmund
Y1  - 2009
N1  - 
T2  - Cosmetic Dermatology: Principles and Practice, 2e
AB  - Hyperpigmented  lesions,  whether  they  are  solar  lentigos,  freckles,  or  melasma,  are  the  source  of  frequent  complaints  by  cosmetic  patients.  In  addition,  some  cosmetic  patients  develop  postinflammatory  hyperpigmentation  after  chemical  peels,  laser  treatments,  or  even  after  a  bout  of  acne.  Melanin  synthesis  within  melanosomes  and  their  distribution  to  keratinocytes  within  the  epidermal  melanin  unit  determines  skin  pigmentation.  Hyperpigmentation  occurs  when  this  system  goes  awry  (see  Chapter  13).  But  dark  spots  and  patches  are  unacceptable  to  cosmetic  patients.  For  this  reason,  there  are  hundreds  of  products  on  the  market  that  are  touted  as  “lightening  creams.”  Although  there  are  many  product  choices  available,  the  number  of  effective  agents  to  treat  hyperpigmentation  disorders  is  relatively  small.  Unfortunately,  most  of  these  agents  require  months  of  use  for  improvement  to  be  seen.  Combination  with  retinoids  (Chapter  30),  sunscreens  (Chapter  29),  chemical  peels  (Chapter  20),  and  lights  or  lasers  (Chapter  24)  may  enhance  the  effectiveness  of  these  products.  Currently  available  topical  agents  used  to  treat  hyperpigmentation  include  tyrosinase  inhibitors,  melanosome-transfer  inhibitors,  melanocyte-cytotoxic  agents,  retinoids,  peeling  agents,  and  sunscreens.  This  chapter  will  discuss  the  ingredients  commonly  used  for  the  treatment  of  pigmentary  disorders.  
SN  - 
PB  - The McGraw-Hill Companies, Inc.
CY  - New York, NY
Y2  - 2024/04/18
UR  - dermatology.mhmedical.com/content.aspx?aid=1172447965
ER  -